跳轉至內容
Merck
全部照片(1)

文件

B3303

Sigma-Aldrich

布舍瑞林 乙酸盐

≥90% (HPLC)

同義詞:

des-Gly10-[D-Ser[t-Bu]6]-LH-RH ethylamide acetate salt, pGlu-His-Trp-Ser-Tyr-D-Ser(t-Bu)-Leu-Arg-Pro-NHEt acetate salt

登入查看組織和合約定價
全部照片(1)

About This Item

經驗公式（希爾表示法）:
C60H86N16O13 · C2H4O2
CAS號碼:
68630-75-1
分子量：:
1299.48
MDL號碼:
MFCD00941414
分類程式碼代碼:
51111800
NACRES:
NA.32

化驗

≥90% (HPLC)

形狀

powder

UniProt登錄號

P12391

儲存溫度

−20°C

InChI

1S/C60H86N16O13.C2H4O2/c1-7-64-57(87)48-15-11-23-76(48)58(88)41(14-10-22-65-59(61)62)69-51(81)42(24-33(2)3)70-56(86)47(31-89-60(4,5)6)75-52(82)43(25-34-16-18-37(78)19-17-34)71-55(85)46(30-77)74-53(83)44(26-35-28-66-39-13-9-8-12-38(35)39)72-54(84)45(27-36-29-63-32-67-36)73-50(80)40-20-21-49(79)68-40;1-2(3)4/h8-9,12-13,16-19,28-29,32-33,40-48,66,77-78H,7,10-11,14-15,20-27,30-31H2,1-6H3,(H,63,67)(H,64,87)(H,68,79)(H,69,81)(H,70,86)(H,71,85)(H,72,84)(H,73,80)(H,74,83)(H,75,82)(H4,61,62,65);1H3,(H,3,4)/t40-,41-,42-,43-,44-,45-,46-,47+,48-;/m0./s1

InChI 密鑰

PYMDEDHDQYLBRT-DRIHCAFSSA-N

基因資訊

rat ... Chrnb3(171131)

尋找類似的產品？ 前往 產品比較指南

Amino Acid Sequence

Glp-His-Trp-Ser-Tyr-Ser-tBu-Leu-Arg-Pro-NHEt

生化／生理作用

Buserelin is an LH-RH agonist.

包裝

Bottomless glass bottle. Contents are inside inserted fused cone.

象形圖

Health hazardExclamation mark
GHS08,GHS07

訊號詞

Danger

危險聲明

H302,H360

危險分類

Acute Tox. 4 Oral - Repr. 1B

儲存類別代碼

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

水污染物質分類（WGK）

WGK 3

閃點（°F）

Not applicable

閃點（°C）

Not applicable

個人防護裝備

Eyeshields, Faceshields, Gloves, type P3 (EN 143) respirator cartridges

分析證明 (COA)

輸入產品批次/批號來搜索 分析證明 (COA)。在產品’s標籤上找到批次和批號，寫有 ‘Lot’或‘Batch’.。

已經擁有該產品？

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

客戶也查看了

Slide 1 of 2

1 of 2

阿苯达唑 Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1281

阿苯达唑

Octreotide ≥98% (HPLC)

Sigma-Aldrich

O1014

Octreotide

Mari Kasai et al.
Fertility and sterility, 98(2), 440-443 (2012-07-04)
To determine correlations between shrinkage of uterine leiomyomas after treatment with GnRH agonists (GnRH-a) or menopause and expression levels of estrogen receptors (ER), progesterone receptors (PR), and vascular endothelial growth factor (VEGF). Cohort study. University teaching hospital. A total of
Christoph Gerlinger et al.
BMC women's health, 12, 9-9 (2012-04-21)
Approaches to the treatment of endometriosis vary worldwide, but studies comparing endometriosis medications in different ethnic groups are rare. A systematic literature search identified two studies directly comparing dienogest (DNG) versus gonadotropin-releasing hormone (GnRH) analogues in European and Japanese populations.
Peter Humaidan et al.
Reproductive biomedicine online, 24(2), 134-141 (2011-12-27)
In stimulated IVF/intracytoplasmic sperm injection cycles, the luteal phase is disrupted, necessitating luteal-phase supplementation. The most plausible reason behind this is the ovarian multifollicular development obtained after ovarian stimulation, resulting in supraphysiological steroid concentrations and consecutive inhibition of LH secretion
Malin Huber et al.
Fertility and sterility, 100(5), 1270-1276 (2013-08-13)
To explore the utility of using the ratio between oocyte yield and total dose of FSH, i.e., the ovarian sensitivity index (OSI), to define ovarian response patterns. Retrospective cross-sectional study. University-affiliated private center. The entire unselected cohort of 7,520 IVF/intracytoplasmic
Elin Sand et al.
Cell and tissue research, 351(3), 521-534 (2012-12-21)
Gonadotropin-releasing hormone (GnRH) analogs are given to women undergoing in vitro fertilization. Case reports describing the development of chronic intestinal pseudo-obstruction and auto-antibodies against GnRH after such treatment suggest a strong association between intestinal dysfunction and GnRH analogs. No experimental
查看所有相關論文

我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務